Efficacy and safety of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase 3, open-label, 2:1 randomized, treat-to-target trial
Diabetes, Obesity and Metabolism | Mar 20, 2019
Effects of lixisenatide on postprandial blood pressure, gastric emptying, and glycemia in healthy people and people with type 2 diabetes
Diabetes, Obesity and Metabolism | Mar 20, 2019
Glycemic control after treatment intensification in patients with type 2 diabetes uncontrolled on two or more non-insulin antidiabetic drugs in a real-world setting
Diabetes, Obesity and Metabolism | Mar 20, 2019
Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin
Diabetes, Obesity and Metabolism | Mar 20, 2019
Achieving LDL cholesterol target levels <1.81 mmol/l may provide extra cardiovascular protection in patients at high risk: Exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients with Hypercholesterolaemia and Diabetic Retinopathy study
Diabetes, Obesity and Metabolism | Mar 20, 2019
Direct medical costs in the preceding, event and subsequent years of first severe hypoglycaemia requiring hospital transfer: A population-based cohort study
Diabetes, Obesity and Metabolism | Mar 20, 2019
Composite cardiovascular risk factor target achievement and its predictors in US adults with diabetes: The Diabetes Collaborative Registry
Diabetes, Obesity and Metabolism | Mar 20, 2019
Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7)
Diabetes, Obesity and Metabolism | Mar 20, 2019